FORM 4

obligations may continue. See

Instruction 1(b)

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PORTER MICHAEL E						2. Issuer Name and Ticker or Trading Symbol  MERRIMACK PHARMACEUTICALS  INC [ MACK ]								5. Relationship of Reporting Person(s) to Iss (Check all applicable) X Director 10% Ov			o Issuer % Owner		
(Last) (First) (Middle) C/O MERRIMACK PHARMACEUTICALS, INC. ONE KENDALL SQUARE, SUITE B7201				1	3. D	3. Date of Earliest Transaction (Month/Day/Year) 11/27/2013									Offic below	er (give title w)		ner (specify ow)	
(Street)  CAMBRIDGE MA 02139  (City) (State) (Zip)					_ 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	-/				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/						Execution Date,			3. Transaction Code (Instr. 8)  4. Securities Disposed O					d 5) Securi Benefi		icially d Following	6. Ownersh Form: Direc (D) or Indire (I) (Instr. 4)	of Indirect Eeneficial Ownership	
									Code	v	Amount	(A) or (D) Price			Trans	action(s) 3 and 4)		(Instr. 4)	
Common Stock 11/27/20					2013	13		P		50,000	A	\$3.50	\$3.5071(1)		27,865	D			
Common Stock 11/29/20					2013	13		P		25,000	A	\$3.79	\$3.7932(2)		352,865				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Conversion Date			if any (Coc (Month/Day/Year) 8)		Transa Code (	Instr.	Securities Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. : and 4)  Amount or Number of		-		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersi Form: Direct (E or Indire (I) (Instr.	Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

- 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$3.4699 to \$3.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.
- 2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$3.72 to \$3.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

/s/ Jeffrey A. Munsie, attorney-12/02/2013 in-fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.